Drug resistance mechanism of carbapenem-resistant Klebsiella pneumoniae to ceftazidime/avibactam and progress in clinical treatment

VernacularTitle:耐碳青霉烯类肺炎克雷伯菌对头孢他啶/阿维巴坦耐药的机制及临床治疗进展
Author: Yanqiu MA ¹ ; Yipeng DU ; Jiajia ZHENG ; Ning SHEN
Author Information

1. 北京大学第三医院呼吸与危重症医学科，北京　100191
Keywords: Carbapenem-resistant Klebsiella pneumoniae; Ceftazidime/avibactam; Drug resistance mechanism; Meropenem/vaborbactam; Cefiderocol
From: Chinese Journal of Microbiology and Immunology 2023;43(12):925-931
CountryChina
Language:Chinese
Abstract: Klebsiella pneumoniae is one of the common pathogens causing hospital-acquired infection. With the wide use of carbapenem in recent years, carbapenem-resistant Klebsiella pneumoniae (CRKP) has emerged around the world. Carbapenemase production is the main cause of resistance to carbapenem antibiotics in Klebsiella pneumoniae. More than 70% of Klebsiella pneumoniae strains produce carbapenemase. Ceftazidime/avibactam (CAZ/AVI) can effectively treat CRKP infection, especially those caused by CRKP that can produce Klebsiella pneumoniae carbapenemase (KPC) or oxaclillinase (OXA)-48. However, it has been reported that CAZ/AVI-resistant CRKP strains have emerged. In this paper, the epidemiology, risk factors, resistance mechanism and treatment of CAZ/AVI-resistant CRKP were summarized to provide reference for clinical treatment.